Patent 9023995 was granted and assigned to Boehringer Ingelheim on May, 2015 by the United States Patent and Trademark Office.
The present invention relates to anti-interleukin-36R (anti-IL-36R) binding compounds, in particular new anti-IL-36R antibodies and therapeutic and diagnostic methods and compositions for using the same.